Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial – CORRIGENDUM

Colleen Loo; Nick Glozier; David Barton; Bernhard Baune; Natalie Mills; Paul Fitzgerald; Paul Glue; Shanthi Sarma; Veronica Galvez-Ortiz; Dusan Hadzi-Pavlovic; Angelo Alonzo; Vanessa Dong; Donel Martin; Stevan Nikolin; Philip Mitchell; Michael Berk; Gregory Carter; Maree Hackett; John Leyden; Sean Hood; Andrew Somogyi; Kyle Lapidus; Elizabeth Stratton; Kirsten Gainsford; Deepak Garg; Nicollette Thornton; Célia Fourrier; Karyn Richardson; Demi Rozakis; Anish Scaria; Cathrine Mihalopoulos; Mary Chatterton; William McDonald; Philip Boyce; Paul Holtzheimer; F Kozel; Patricio Riva-Posse; Anthony Rodgers

doi:10.1192/bjp.2024.189

Back

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial – CORRIGENDUM

Journal article

Open access

Peer reviewed

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial – CORRIGENDUM

Colleen Loo, Nick Glozier, David Barton, Bernhard Baune, Natalie Mills, Paul Fitzgerald, Paul Glue, Shanthi Sarma, Veronica Galvez-Ortiz, Dusan Hadzi-Pavlovic, …

British journal of psychiatry, Vol.225(2), pp.349-349

01/08/2024

DOI: https://doi.org/10.1192/bjp.2024.189

Handle:

https://hdl.handle.net/10523/42990

Abstract

Efficacy

Ketamine

correction

Loo C, Glozier N, Barton D, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. The British Journal of Psychiatry. 2023;223(6):533-541. doi:10.1192/bjp.2023.79 This article was originally published with an error in the outcome of blinding assessment results. The paper reported outcomes for the evaluation of blinding at the end of the 4-week RCT, but the data used was from the evaluation done after treatment one, rather than the end of RCT timepoint. The errors have been rectified in the online versions of the article and linked supplementary material.

Files and links (2)

pdf

efficacy-and-safety-of-a-4-week-course-of-repeated-subcutaneous-ketamine-injections-for-treatment-resistant-depression-kads-study-randomised-double-blind-active-controlled-trial-corrigendum153.58 kBDownload View

Published (Version of record)CC BY V4.0, Open Access

url

https://doi.org/10.1192/bjp.2024.189View

Published (Version of record) Open

Metrics

2 File views/ downloads

13 Record Views

Details

Record Identifier: 9926613397401891
Title: Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial – CORRIGENDUM
Creators: Colleen Loo
Nick Glozier
David Barton
Bernhard Baune
Natalie Mills
Paul Fitzgerald
Paul Glue
Shanthi Sarma
Veronica Galvez-Ortiz
Dusan Hadzi-Pavlovic
Angelo Alonzo
Vanessa Dong
Donel Martin
Stevan Nikolin
Philip Mitchell
Michael Berk
Gregory Carter
Maree Hackett
John Leyden
Sean Hood
Andrew Somogyi
Kyle Lapidus
Elizabeth Stratton
Kirsten Gainsford
Deepak Garg
Nicollette Thornton
Célia Fourrier
Karyn Richardson
Demi Rozakis
Anish Scaria
Cathrine Mihalopoulos
Mary Chatterton
William McDonald
Philip Boyce
Paul Holtzheimer
F Kozel
Patricio Riva-Posse
Anthony Rodgers
Publication Details: British journal of psychiatry, Vol.225(2), pp.349-349
Academic Unit: Psychological Medicine (DSM)
Publisher: Cambridge University Press
Date published ; e-published: 01/08/2024
Copyright: Copyright © The Author(s) 2024. This work was first published in The British Journal of Psychiatry (Cambridge University Press). This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://www.creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, provided that the original work is properly attributed to the creator(s) and the source, a link to the Creative Commons license is provided, and any changes made are indicated.
Language: English
Resource Type ; Subtype: Journal article

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial – CORRIGENDUM

Abstract

Files and links (2)

Related content

Metrics

Details